homepage-top-section

Through the expanded agreement, Humanigen will now gain access to manufacturing capacity reserved by the Biomedical Advanced Research and Development Authority (BARDA) for the development of lenzilumab as

The Sputnik V vaccine was registered under the emergency use authorisation procedure based on the results from the Russian Phase III clinical trials on more than 33,000 people.

The rapidly fast-spreading B.1.1.7 lineage, a variant strain of SARS-CoV-2 detected initially in the UK, has ten mutations located in the spike protein. The two firms had earlier

Novartis and GSK have agreed to provide £2.8m ($3.6m) for the Africa Genomic Research Approach for Diversity and Optimizing Therapeutics (GRADIENT) project (Project Africa GRADIENT), over the next

Etana now has the right to sell BYVASDA in the country and in return, Innovent Biologics will receive milestones for the development and commercialisation along with double-digit royalties

The viral vector manufacturing arm of Novasep offers contract manufacturing services for vaccines and therapies to biotechnology and biopharma companies. Established over 20 years ago, the business has

The approval enables to use of ligelizumab to treat CSU, also called chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment. CSU is

Based in New York, Prevail develops and commercialises disease-modifying Adeno-associated viruses (AAV) based gene therapies to treat neurodegenerative diseases. Under the deal, Eli Lilly will acquire Prevail by paying

As per terms of the proposed deal, the EC can increase their purchase of Covid-19 vaccine from 80 million doses to a total of up to 160 million